文献速递淋巴瘤

双特异性抗体治疗B细胞淋巴瘤:前景、未知与机遇

Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities.
PubMed 文献 · Blood · 2023-01-01

本文综述了双特异性抗体(BsAb)治疗B细胞非霍奇金淋巴瘤(B-NHL)的研发与临床应用进展,重点介绍抗CD20xCD3 BsAb在经重度预处理患者中单药活性显著且毒性以T细胞过度活化综合征为主,并指出最佳应用场景、联合策略及药效生物标志物等尚待明确。

要点

  • 抗CD20xCD3双特异性抗体在经重度预处理的B细胞非霍奇金淋巴瘤患者中显示出显著的单药活性。
  • 抗CD20xCD3双特异性抗体的毒性以T细胞过度活化综合征为主,整体可控。
  • 双特异性抗体的最佳应用场景、理想联合方案及药效生物标志物尚待明确。

核心结论

  • 双特异性抗体是现成可用的T细胞重定向药物,是当前淋巴瘤最有前景的免疫治疗之一。
  • 抗CD20xCD3双特异性抗体在经重度预处理的B细胞非霍奇金淋巴瘤中单药活性显著,毒性以T细胞过度活化综合征为主且可控。
  • 双特异性抗体在B细胞非霍奇金淋巴瘤中的最佳应用场景、理想联合伙伴、毒性最小化策略及药效生物标志物仍需进一步研究明确。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 近20年来,随着利妥昔单抗等高活性免疫疗法的引入,B细胞非霍奇金淋巴瘤的治疗范式发生了巨大变化。
  • 嵌合抗原受体T细胞疗法已获监管批准并在这些疾病的治疗中发挥重要作用。
  • 双特异性抗体可靶向多种细胞表面抗原并存在不同形式。
  • 抗CD20xCD3双特异性抗体在经重度预处理的B细胞非霍奇金淋巴瘤患者中显示出显著的单药活性,毒性以T细胞过度活化综合征为主且可控。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have shifted dramatically in the last 2 decades following the introduction of highly active immunotherapies such as rituximab. Since then, the field has continued to witness tremendous progress with the introduction of newer, more potent immunotherapeutics, including chimeric antigen receptor T-cell therapy, which have received regulatory approval for and currently play a significant role in the treatment of these diseases. Bispecific antibodies (BsAb) are a novel class of off-the-shelf T-cell redirecting drugs and are among the most promising immunotherapeutics for lymphoma today. BsAb may target various cell-surface antigens and exist in different formats. Anti-CD20xCD3 BsAb have demonstrated remarkable single-agent activity in patients with heavily pretreated B-NHL with a manageable toxicity profile dominated by T-cell overactivation syndromes. Much work remains to be done to define the optimal setting in which to deploy these drugs for B-NHL treatment, their ideal combination partners, strategies to minimize toxicity, and, perhaps most importantly, pharmacodynamic biomarkers of response and resistance. In this review, we provide an update on BsAb development in B-NHL, from discovery to clinical applications, highlighting the achievements, limitations, and future directions of the field.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Falchi L, Vardhana SA, Salles GA, et al. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023. PMID: 36322929. doi:10.1182/blood.2021011994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。